Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Meningioma DNA methylation grouping reveals biologic drivers and therapeutic vulnerabilities

ABSTRACT: Meningioma DNA methylation grouping reveals biologic drivers and therapeutic vulnerabilities

PROVIDER: PRJNA761585 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15808800.fastq.gz	Fastqsanger.gz
	SRR15808900.fastq.gz	Fastqsanger.gz
	SRR15808801.fastq.gz	Fastqsanger.gz
	SRR15808901.fastq.gz	Fastqsanger.gz
	SRR15808802.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 200

Similar Datasets

Meningioma DNA methylation grouping reveals biologic drivers and therapeutic vulnerabilities (array)

Project description:Meningioma DNA methylation grouping reveals biologic drivers and therapeutic vulnerabilities (array)

| PRJNA761489 | ENA

Meningioma DNA methylation grouping reveals biologic drivers and therapeutic vulnerabilities (array)

Project description:We report DNA methylation profiling on 565 meningiomas integrated with genetic, transcriptomic, biochemical, proteomic, and single-cell approaches to show meningiomas are comprised of 3 groups with distinct clinical outcomes, biological drivers, and therapeutic vulnerabilities. Merlin-intact meningiomas have the best outcomes and are distinguished by NF2/Merlin regulation of glucocorticoid signaling, apoptosis, and susceptibility to cytotoxic therapy. Immune-enriched meningiomas have intermediate outcomes and are distinguished by immune infiltration, HLA expression, and lymphatic vessels. Hypermitotic meningiomas have the worst outcomes and are distinguished by convergent genetic and epigenetic mechanisms driving the cell cycle and resistance to cytotoxic therapy. Our results establish a framework for understanding meningioma biology, and provide a foundation for new meningioma treatments.

2022-01-10 | GSE183647 | GEO

Meningioma DNA methylation grouping reveals biologic drivers and therapeutic vulnerabilities

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-01-10 | GSE183656 | GEO

Multisite methylation profiling of primary human meningioma

Project description:Multiple stereotatically separate sites from human meningioma were processed for methlyation profiling Meningiomas are the most common primary intracranial tumors, but the molecular drivers of meningioma tumorigenesis are poorly understood. We hypothesized that investigating intratumor heterogeneity in meningiomas would elucidate biologic drivers and reveal new targets for molecular therapy. To test this hypothesis, we performed multiplatform molecular profiling of 86 spatially-distinct samples from 13 human meningiomas. Our data reveal that regional alterations in chromosome structure underlie clonal transcriptomic, epigenomic, and histopathologic signatures in meningioma. Stereotactic co-registration of sample coordinates to preoperative magnetic resonance images further demonstrated that high apparent diffusion coefficient (ADC) distinguished meningioma regions with proliferating cells enriched for developmental gene expression programs. To understand the function of these genes in meningioma, we developed a human cerebral organoid model of meningioma and validated the high ADC marker genes CDH2 and PTPRZ1 as potential targets for meningioma therapy using live imaging, single cell RNA sequencing, CRISPR interference, and pharmacology.

2020-06-17 | GSE151067 | GEO

Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.

Project description:Meningiomas are the most common primary intracranial tumors. There are no effective medical therapies for meningioma patients, and new treatments have been encumbered by limited understanding of meningioma biology. Here, we use DNA methylation profiling on 565 meningiomas integrated with genetic, transcriptomic, biochemical, proteomic and single-cell approaches to show meningiomas are composed of three DNA methylation groups with distinct clinical outcomes, biological drivers and therapeutic vulnerabilities. Merlin-intact meningiomas (34%) have the best outcomes and are distinguished by NF2/Merlin regulation of susceptibility to cytotoxic therapy. Immune-enriched meningiomas (38%) have intermediate outcomes and are distinguished by immune infiltration, HLA expression and lymphatic vessels. Hypermitotic meningiomas (28%) have the worst outcomes and are distinguished by convergent genetic and epigenetic mechanisms driving the cell cycle and resistance to cytotoxic therapy. To translate these findings into clinical practice, we show cytostatic cell cycle inhibitors attenuate meningioma growth in cell culture, organoids, xenografts and patients.

| S-EPMC9374001 | biostudies-literature

Identification of drivers and therapeutic vulnerabilities in anti-androgen resistant prostate cancer cells

Project description:Identification of drivers and therapeutic vulnerabilities in anti-androgen resistant prostate cancer cells

| PRJNA540539 | ENA

Human meningioma culture

Project description:Comparison of the gene expression profiles with meningiomas of different grading. 24 primary meningioma cultures from surgical specimen were maintained to primary meningioma cultures.

2014-03-06 | E-GEOD-55609 | biostudies-arrayexpress

Whole genome expression in meningioma

Project description:We performed expression profiling of 24 meningioma and two dura controls analyzing 55000 transcripts including 18300 known genes. We compared expression in meningioma vs. dura, expression of low grade (WHO I) vs. higher-grade (WHO II and WHO IIII) tumors and expression of meningothelial and syncytial meningioma vs. fibroblastic meningioma. Gene expression was analysed in 24 meningioma including eight of each WHO grade and two dura controls analyzing 55000 transcripts including 18300 known genes.

2008-11-20 | E-GEOD-12530 | biostudies-arrayexpress

Genetic Screen in a Pre-Clinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities

Project description:Genetic Screen in a Pre-Clinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities

| PRJNA948826 | ENA

Meningioma methylation data

Project description:Methylation analysis of meningioma cases Genomic DNA isolated directly from human meningioma samples

2024-08-21 | GSE270371 | GEO